5th Oligonucleotides Analytical Development and CMC

Memo

As oligonucleotide therapeutics expand across ASOs, siRNA, gRNA, and increasingly complex conjugates, the field is entering a new phase of clinical and commercial maturity. However, with this progress comes heightened complexity across analytical characterization, impurity profiling, stereochemistry, and control strategy definition, increasing pressure for development teams to deliver robust, scalable, and regulatory-ready CMC packages.With evolving European and Chinese guidance and increasing global expectations for analytical depth, comparability, and justification of control strategies, success now hinges on the ability to the ability to predict, monitor, and control impurity formation throughout development and manufacturing.To meet these demands, the 5th Oligonucleotide Analytical Development and CMC Summit returns to unite 90+ leaders across Analytical Development, CMC, Quality Control, Process Development, and Regulatory Affairs to define best practices and establish the next standard for oligonucleotide control strategies.URLs:Tickets: https://go.evvnt.com/3602557-2?pid=5569Brochure: https://go.evvnt.com/3602557-3?pid=5569Date and Time: On Monday August 17, 2026 at 8:30 am to Wednesday August 19, 2026 at 3:05 pmVenue details: The Colonnade Hotel, 120 Huntington Avenue, Boston, Massachusetts, 02116, United StatesPrices:Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day): USD 4397.00,Drug Developer Pricing - 2 Day Pass (Conference Only): USD 3099.00,Academic Pricing - 3 Day Pass (Conference + Workshop Day): USD 3797.00,Academic Pricing - 2 Day Pass (Conference Only): USD 2699.00,Solution Provider Pricing - 3 Day Pass (Conference + Workshop Day): USD 5297.00,Solution Provider Pricing - 2 Day Pass (Conference Only): USD 3799.00Speakers: Jinyi Yang, Senior Scientist, Amgen, Bharath Venkatram, Senior Engineer - Process Development and Scale up Lab, Amgen , Zifan Li, Senior Scientist, Biogen, George Bou-Assaf, Associate Director, Biogen, Fenghe Qiu, Director - External Alternative Chemistry, Manufacturing and Controls Development, Boehringer Ingelheim, Jennifer Nguyen, Associate Director, Alnylam Pharmaceuticals, Catalina Parga, Process Development Scientist, Alnylam Pharmaceuticals, Matthew McQueen, Associate Director, Analytical Development, Avidity Biosciences, Satya Kuchimanchi, Senior Vice President - Technical Operations, Chemistry, Manufacturing, and Controls, CAMP4 Therapeutics, Paul Peng, Vice President - Chemistry, Manufacturing and Controls, City Therapeutics, Yanjie Jiang, Director - Chemistry Manufacturing Control and Analytical Development, City Therapeutics, Kok Seong Lim, Independent Cell and Gene Therapy CMC Expert, Independent Expert, Bethany Okada, Associate Director Analytical Development Quality Control, Ionis Pharmaceuticals, Inc., Hagen Cramer, Chief Technology Officer, QurAlis, Ying Xu, Head of Analytical Sciences, Souffle Therapeutics, Brooke Koshel, Director - Process Development, Wave Life Sciences Ltd., Shaimaa Ahmadeen, Scientific evaluation expert, Saudi FDA